Nelarabine (506U78) 是一种核苷类似物 (nucleoside analogue)，可用于 T 细胞急性淋巴细胞白血病的研究。
| 生物活性 | Nelarabine (506U78) is anucleoside analogueand can be used for the research of T cell acute lymphoblastic leukemia (T-ALL)[1]. |
体外研究
(In Vitro) | Nelarabine (506U78) (0-20 μM; 48 h) induces cytotoxic effects in T-ALL cell lines[1].
Nelarabine (5 or 2 μM; 48 h) promotes apoptosis in sensitive T-ALL cell lines and modulates PI3K/AKT/mTOR and MEK signaling[1].
Nelarabine (10 μM; 0-48 h) resistance does not depend on expression of ENT1/2 transporters and is partly due to upregulation of PI3K, MEK, and Bcl2 signaling[1].
Cell Viability Assay[1] | Cell Line: | T-ALL cell lines | | Concentration: | 0-20 μM | | Incubation Time: | 48 h | | Result: | Cell viability decreased in a concentration-dependent fashion, and the IC50values ranged between 2 and 5.5 μM for sensitive cell lines (MOLT-4, HSB-2, P12, DND41, JURKAT). |
Apoptosis Analysis[1] | Cell Line: | MOLT-4, JURKAT, P12-ICHIKAWA and DND41 | | Concentration: | 5 μM (2 μM for MOLT-4 cells) | | Incubation Time: | 48 h | | Result: | Detected a marked increase in the percentage of early apoptotic and/or late apoptotic cells. |
Western Blot Analysis[1] | Cell Line: | MOLT-4, JURKAT, P12-ICHIKAWA and DND41 | | Concentration: | 5 μM (2 μM for MOLT-4 cells) | | Incubation Time: | 0, 6, 16, 24 and 48 h | | Result: | Documented a time-dependent cleavage of caspase 8, caspase 9, caspase 3, and poly(ADP-ribose) polymerase (PARP) in response to drug treatment.
Induced a marked decrease of phosphorylated AKT at Ser473, S6 ribosomal protein (S6RP) at Ser235/236, and GSK3β at Ser9. |
|
体内研究
(In Vivo) | Nelarabine (506U78) (130 mg/kg/day; i.v.; 5 days) reduces leukemic burden and extends mouse survival in NSG mice xenografted with luciferase-expressing U937 cells[2].
| Animal Model: | NSG mice xenografted with luciferase-expressing U937 cells[2] | | Dosage: | 130 mg/kg/day | | Administration: | Intravenous injection, 5 days | | Result: | Reduced leukemic burden and extended mouse survival. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(336.39 mM;Need ultrasonic) H2O : 10 mg/mL(33.64 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.3639 mL | 16.8197 mL | 33.6395 mL | | 5 mM | 0.6728 mL | 3.3639 mL | 6.7279 mL | | 10 mM | 0.3364 mL | 1.6820 mL | 3.3639 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 5 mg/mL (16.82 mM); Clear solution; Need ultrasonic and warming and heat to 60℃ 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (8.41 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (8.41 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (8.41 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (8.41 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 4. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (8.41 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (8.41 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
